Michael Partin, MD
Interventional Cardiology · Oklahoma City, OKNPI 1427090232
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 489 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations.
Across 489 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- AstraZeneca$1K
- Johnson & Johnson$1K
- Amgen$844
- Novartis$765
- Merck$763
- plus $3K from 17 others
What the payments were for
- Food & beverage$8,88499%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 65 | $1,213 |
| AstraZeneca | 69 | $1,201 |
| Johnson & Johnson | 72 | $1,192 |
| Amgen | 38 | $844 |
| Novartis | 42 | $765 |
| Merck | 41 | $763 |
| Pfizer | 48 | $736 |
| Boehringer Ingelheim | 33 | $615 |
| E.r. Squibb & Sons, L.L.C. | 28 | $497 |
| Actelion Pharmaceuticals US, Inc. | 9 | $177 |
| Abbott | 6 | $149 |
| Sanofi-aventis U.S. LLC | 8 | $140 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $105 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $92 |
| Boston Scientific | 4 | $91 |
| Medtronic | 2 | $80 |
| Irhythm Technologies, Inc. | 5 | $71 |
| Bayer | 2 | $52 |
| Novo Nordisk | 3 | $48 |
| Vifor Pharma, Inc. | 2 | $41 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| Chiesi USA, Inc. | 1 | $15 |
How this compares
$8,936 in reported general payments places this provider in the 60th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 809 | $914,959 |
| EntrestoSacubitril/Valsartan | 191 | $265,817 |
| XareltoRivaroxaban | 164 | $186,194 |
| Prasugrel Hcl | 774 | $73,208 |
| FarxigaDapagliflozin Propanediol | 63 | $68,049 |
| Repatha SureclickEvolocumab | 73 | $58,577 |
| JardianceEmpagliflozin | 40 | $31,788 |
| VerquvoVericiguat | 25 | $31,471 |
| Metoprolol Succinate | 1,360 | $21,928 |
| Losartan Potassium | 917 | $16,876 |
| Atorvastatin Calcium | 1,013 | $15,701 |
| ClopidogrelClopidogrel Bisulfate | 1,040 | $14,587 |
| Terazosin Hcl | 464 | $12,074 |
| Praluent PenAlirocumab | 21 | $11,683 |
| Ranolazine ErRanolazine | 105 | $11,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $736 | $914,959809 claims |
| NovartisEntresto | $765 | $265,817191 claims |
| Johnson & JohnsonXarelto | $1,192 | $186,194164 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,201 | $75,03074 claims |
| Boehringer IngelheimJardiance | $615 | $31,78840 claims |
| MerckVerquvo | $763 | $31,47125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Marcus SmithOklahoma City$67K
- Parker TruongOklahoma City$44K
- Mohammad GhaniOklahoma City$38K
- Timothy DalyOklahoma City$31K
- Branislav SchifferdeckerOklahoma City$26K
- Mohit PahujaOklahoma City$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.